CJC-1295 (NO DAC)
CJC-1295 (NO DAC)

Home

/

Shop

/

CJC-1295 (NO DAC)

CJC-1295 (NO DAC)
CJC-1295 (NO DAC)
CJC-1295 (NO DAC)
CJC-1295 (NO DAC)
CJC-1295 (NO DAC)
CJC-1295 (NO DAC)

CJC-1295 (NO DAC)

£19.00Sold out
Out of stock
Size
1
ABOUT THIS COMPOUND
Description

CJC-1295 (without DAC), widely recognized in scientific literature as Modified GRF 1-29, from Super Human Peptides UK is a highly advanced, synthetic Growth Hormone-Releasing Hormone (GHRH) analogue. In laboratory research, native GHRH is nearly useless for long-term modeling because it is rapidly cleaved and destroyed by the dipeptidyl peptidase-4 (DPP-4) enzyme within 5 minutes. Researchers utilize CJC-1295 (without DAC) because it features four specific amino acid substitutions (tetrasubstituted) that physically shield it from DPP-4 degradation.

This engineering extends its active biological half-life to approximately 30 minutes. Unlike the DAC version—which causes a continuous, unnatural "bleed" of growth hormone—this specific 30-minute window perfectly mimics the body's natural rhythm, triggering a massive but natural physiological pulse of Growth Hormone (GH). Produced under GMP-compliant conditions and verified for 99% purity or higher, it is an elite tool for advanced preclinical research into episodic GH secretion, slow-wave sleep architecture, and synergistic endocrine modeling.

WarningFor laboratory research use only. Not for human consumption.
Key Features
  • —Tetrasubstituted Engineering: Features four distinct amino acid replacements to prevent rapid enzymatic destruction by DPP-4.
  • —Natural Pulsatile Rhythm: Maintains an optimal 30-minute half-life to trigger a massive, episodic GH spike that mimics natural pituitary function.
  • —Prevents Receptor Desensitization: Because it clears the system rapidly, it prevents the down-regulation of GHRH receptors often seen with long-acting continuous agonists.
  • —Synergistic Baseline: The premier GHRH utilized in combination modeling with Growth Hormone-Releasing Peptides (like Ipamorelin or GHRP-6) to bypass somatostatin blocks.
  • —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
  • —Quality Standard: GMP / ISO certified manufacturing.
Research Focus
  • —Episodic Pharmacokinetics: Studying the rapid onset, peak, and clearance of circulating Growth Hormone and IGF-1 to model natural circadian endocrinology.
  • —Slow-Wave Sleep Architecture: Investigating the peptide's role in deepening the delta-wave sleep phase, which is the primary biological window for memory consolidation and tissue repair.
  • —Receptor Up-Regulation: Measuring the sustained sensitivity of pituitary somatotrophs when exposed to intense, short-duration GHRH agonism versus continuous saturation.
  • —Lipolysis and Visceral Fat: Preclinical models exploring the acute mobilization of free fatty acids from white adipose tissue immediately following an induced GH pulse.
  • —Cellular Senescence: Evaluating the peptide's ability to maintain youthful metabolic turnover and protein synthesis in naturally aged animal models.
Published Research and Study Findings

The development of Modified GRF 1-29 was a pivotal moment in peptide endocrinology. Originally, researchers isolated the active 29-amino-acid core of native Growth Hormone-Releasing Hormone (known as GRF 1-29 or Sermorelin). However, because Sermorelin is destroyed in less than 10 minutes by blood enzymes, it required constant, impractical administration to yield results.

By substituting four specific amino acids (at positions 2, 8, 15, and 27), researchers successfully blocked the DPP-4 enzyme from cleaving the chain. In laboratory and clinical modeling, this tetrasubstituted peptide—CJC-1295 without DAC—demonstrated the ability to safely survive in the bloodstream just long enough to reach the anterior pituitary and trigger a maximal GH release. Studies confirmed that this transient 30-minute activation is the exact biological duration required to stimulate intense tissue repair and lipolysis without disrupting the body's natural negative feedback loops.

NoteAll findings are derived from laboratory and non-clinical research settings.
Representative Scientific References
  • 1.Jette, L. et al., "Human growth hormone-releasing hormone (hGHRH) 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats," Endocrinology, 2005. (Details the structural substitutions required for stability).
  • 2.Campbell, R.M. et al., "Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human sequences," Peptides, 1991.
  • 3.Martin, J.B., "Neural regulation of growth hormone secretion," The New England Journal of Medicine, 1973. (Contextual physiology of pulsatile GH).
  • 4.Alba-Roth, J. et al., "Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion," The Journal of Clinical Endocrinology & Metabolism, 1988. "By clicking 'Add to Cart,' I certify that I am purchasing this product for laboratory research use only and agree to the Terms of Service regarding non-human consumption.".
Technical data
Specifications
Purity
≥99%, HPLC verified
Form
Lyophilised white powder
Molecular formula
See batch COA
Molecular weight
See batch COA
SKU
SHP-CJC1295-NODAC-001-10
Research category
Secretagogues
Storage
-20°C, protected from light
Reconstitution
Reconstitute with bacteriostatic water; swirl gently, do not shake
Research use
In-vitro laboratory research only. Not for human consumption.
Common questions
Frequently asked questions
CJC-1295 (NO DAC) is a synthetic GHRH analogue with four amino acid substitutions that protect it from DPP-4 degradation, giving an active half-life of approximately 30 minutes. It is supplied lyophilised at ≥99% purity.
It is investigated for physiological growth hormone pulsing, slow-wave sleep models, and synergistic somatotroph activation when combined with a GHRP in controlled laboratory settings.
CJC-1295 (NO DAC) is supplied at ≥99% purity, verified by HPLC with mass-spectrometry identity confirmation. Testing is carried out per batch rather than per product line, so the figures on your certificate of analysis relate to the exact lot in your vial.
Store the sealed vial at -20°C, protected from light. Once reconstituted, the solution should be kept refrigerated at 2-8°C, protected from light, and treated as a short-lived working preparation rather than a long-term stock.
CJC-1295 (NO DAC) is supplied lyophilised. Reconstitute with bacteriostatic water; swirl gently, do not shake, and allow the powder to dissolve fully before use. Direct the solvent down the inside wall of the vial rather than onto the pellet, and record the volume used so working concentrations can be calculated. This applies to in-vitro laboratory work only.
The two act on separate receptors. CJC-1295 (NO DAC) works at the GHRH receptor while Ipamorelin works at the ghrelin receptor, so combining them lets researchers examine additive somatotroph activation across two pathways. The pre-blended Ipamorelin + CJC-1295 No DAC listing exists for exactly that protocol.
Yes. A certificate of analysis covering HPLC purity and mass-spectrometry identity is available for every batch of CJC-1295 (NO DAC). Each vial carries a batch number on its label, and quoting that number lets us send you the certificate that matches the material you hold rather than a generic example.
Exact mass data for CJC-1295 (NO DAC) is quoted on the certificate of analysis issued with the batch you receive, since figures vary slightly by production lot. Contact us before ordering if you need the values in advance.
CJC-1295 (NO DAC) ships from the UK to UK research addresses, with tracked dispatch and insulated packaging. It is sold for in-vitro laboratory research only: it is not a medicine, not a supplement, and not for human or veterinary consumption. Orders are accepted on the basis that the buyer is a qualified researcher.